205 related articles for article (PubMed ID: 26683593)
1. Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-β1.
Chen J; Bai Q; Zhao Z; Sui H; Xie X
J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):549-55. PubMed ID: 26683593
[TBL] [Abstract][Full Text] [Related]
2. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
Qin Z; Chen L; Liu M; Tan H; Zheng L
Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
[TBL] [Abstract][Full Text] [Related]
3. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats.
Cai Y; Liu X; Chen W; Wang Z; Xu G; Zeng Y; Ma Y
Exp Neurol; 2015 Apr; 266():120-6. PubMed ID: 25708985
[TBL] [Abstract][Full Text] [Related]
5. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
[TBL] [Abstract][Full Text] [Related]
6. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
[TBL] [Abstract][Full Text] [Related]
7. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
Saqqur M; Molina CA; Salam A; Siddiqui M; Ribo M; Uchino K; Calleja S; Garami Z; Khan K; Akhtar N; O'Rourke F; Shuaib A; Demchuk AM; Alexandrov AV;
Stroke; 2007 Jan; 38(1):69-74. PubMed ID: 17138949
[TBL] [Abstract][Full Text] [Related]
8. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
9. Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
Pfeilschifter W; Kashefiolasl S; Lauer A; Steinmetz H; Foerch C
Neuroscience; 2013 Oct; 250():181-8. PubMed ID: 23856067
[TBL] [Abstract][Full Text] [Related]
10. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
Osaki M; Miyashita F; Koga M; Fukuda M; Shigehatake Y; Nagatsuka K; Minematsu K; Toyoda K
Eur J Neurol; 2014 Mar; 21(3):411-8. PubMed ID: 24200315
[TBL] [Abstract][Full Text] [Related]
11. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
Takagi T; Kato T; Sakai H; Nishimura Y
J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
Yan X; Hu HT; Liu S; Sun YH; Gao X
Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
[TBL] [Abstract][Full Text] [Related]
13. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
[TBL] [Abstract][Full Text] [Related]
14. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry.
Makihara N; Okada Y; Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Hasegawa Y; Kario K; Okuda S; Naganuma M; Toyoda K
Cerebrovasc Dis; 2012; 33(3):240-7. PubMed ID: 22261711
[TBL] [Abstract][Full Text] [Related]
15. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
[TBL] [Abstract][Full Text] [Related]
16. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
Brown DL; Barsan WG; Lisabeth LD; Gallery ME; Morgenstern LB
Ann Emerg Med; 2005 Jul; 46(1):56-60. PubMed ID: 15988427
[TBL] [Abstract][Full Text] [Related]
17. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
[TBL] [Abstract][Full Text] [Related]
18. Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.
Wang L; Cao D; Wu H; Jia H; Yang C; Zhang L
Clin Appl Thromb Hemost; 2019; 25():1076029619871359. PubMed ID: 31434498
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
Cocho D; Borrell M; Martí-Fàbregas J; Montaner J; Castellanos M; Bravo Y; Molina-Porcel L; Belvís R; Díaz-Manera JA; Martínez-Domeño A; Martínez-Lage M; Millán M; Fontcuberta J; Martí-Vilalta JL
Stroke; 2006 Apr; 37(4):996-9. PubMed ID: 16497981
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial.
Wang XH; You YP
Clin Neuropharmacol; 2017; 40(1):24-28. PubMed ID: 27941526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
